Shwetal Mehta

Just saw the announcement. So sorry to hear this.

Our PK-triggered Phase 0 hybrid trials require extensive assay development and validation. Today Dr. Karapetyan is presenting two posters from @ivycenter.bsky.social on PK assay validation for EGFR inhibitor BDTX-1535 and mTOR inhibitor, Temsirolimus. #AACR2025

Fantastic session on Hippo signaling in cancer at the AACR annual meeting. Exciting talks from Georg Halder, Kun-Liang Guan and William Hahn. The talk on the paradoxical data from YAP knockouts vs TEAD inhibitors was very insightful. #AACR2025

Susan Histed presenting first of five posters being presented at the AACR Annual Meeting from @ivycenter.bsky.social Her work focuses on preclinical drug combination studies in glioma models. #AACR2025

AACR takes great pride in bringing together people with diverse expertise to accelerate progress across the entire spectrum of cancer research. AACR President Patricia LoRusso addresses the #AACR25 Opening Ceremony.

Dr Larry Salzman, a physician and cancer survivor emphasized the importance of accessible clinical trials and cancer research for bringing new treatment options for cancer patients upon receiving the Distinguished Public Service award. #AACR2025

.@YoshieUmemura from @IvyBrainTumCtr presenting our PK/PD data from Phase 0/1 trial of AZD1390 which provides support for a phase 2/3 trial. #sno2024

After 6 years of being involved in early phase clinical trials, I was honored to present data from our Phase 0/2 study exploring CDK4/6i +ERKi in rGBM patients. Grateful to the collaborative team, patients and their families #SNO2024

Meet Ivy Brain Tumor Center At The SNO Meeting 2024 Ivy Brain Tumor Center clinicians, scientists and researchers will participate at the Society for Neuro-Oncology (SNO) Meeting November 21-24 2024 in Houston TX.

Dr. An-Chi Tien from Ivy Center will be presenting compelling results from our Phase 0/1 study of BDTX-1535 in recurrent GBM patients with EGFR alterations at #SNO2024.

📍 Stop by the Poster Session in Hall B3, or explore our research at loom.ly/ciiEqXY 🧠

Great to hear Douglas Hanahan give the Keynote talk at #SNO2024. Remembering the time in 2020 when we did some of these drug testing in GBM PDX models at Ivy Center.

Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma - Nature The prodrug gliocidin effectively kills glioblastoma cells by targeting de novo purine synthesis, improving survival in mouse models.

Right on time to discuss at #SNO2024: Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma. www.nature.com/articles/s41...